C-U8L6OS-01 peptide, cellular senescence, skin aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Support OneSkin's skin aging claims by measuring or modeling biological skin age in its R&D platform.
Proprietary MolClock method referenced by the company as part of its scientific support for OS-01 and skin aging studies.
Listed in supplied site analysis as a proprietary method supporting claims around OS-01 and healthy skin aging.
Reduce visible signs of aging around the eyes, including fine lines, wrinkles, under-eye puffiness, dark circles, reduced firmness, and reduced elasticity.
A topical periorbital formulation containing OS-01 and other active ingredients, evaluated in a 12-week clinical study with 22 participants applying the product twice daily.
2025 publication reported clinical efficacy of OS-01 EYE in reducing signs of periorbital skin aging.
After 12 weeks, supplied evidence reports TEWL decreased 17.33%, hydration increased 32.49%, firmness improved 10.19%, elasticity increased 25.58%, and 95.46% of participants reported improved overall appearance.
Evaluate whether OS-01 peptide treatment reduces biological age and senescence burden in human skin models.
Preclinical research using human skin models to assess senotherapeutic peptide effects on biological age and cellular senescence burden.
2023 publication titled "Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models" listed by OneSkin.
Supplied title indicates reduced biological age and senescence burden in human skin models; no detailed abstract or numeric results were supplied.
Improve healthy skin aging by reducing cellular senescence-related skin changes, including wrinkles, loss of elasticity, uneven tone, rough texture, volume loss, thinning skin, hydration, and barrier function.
Topical formulation containing OS-01, described as a senotherapeutic or senomorphic peptide; evaluated through in-house R&D, human skin models, and clinical studies.
2025 publications reported OS-01 topical formulation results in periorbital skin aging and a 12-week pilot trial on skin barrier function, systemic inflammation markers, and biological age measures.
Supplied evidence reports improved hydration, transepidermal water loss, firmness, elasticity, appearance ratings, skin barrier function, and trends toward normalized inflammatory cytokines in OS-01-treated groups.
Model skin aging and support evaluation of OS-01 peptide effects on biological age and senescence burden.
Proprietary Skin Age Modeling method used within OneSkin's in-house R&D platform.
Referenced in supplied site analysis as part of the company's R&D platform supporting clinical studies, patents, and peer-reviewed publications.